NICE was forced to release details of the economic model it used to assess the drugs in November 2008.
Its independent advisory committee concluded that, although technical inaccuracies were found, these were not sufficient to change the decision that the treatments are not cost-effective for mild Alzheimer's.
NICE's guidance on donepezil, galantamine and rivastigmine and memantine remains unchanged.
NICE chief executive Andrew Dillon said: 'NICE was not asked by the Court of Appeal to carry out a new appraisal.
'However, we regularly review guidance to take into account new evidence and, as long as no appeals are received, a review can start as soon as possible,' he added.